Search International and National Patent Collections
Refine Search
Query Tree
Save query
A private query is only visible to you when you are logged-in and can not be used in RSS feeds
Results 1-10 of 394 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 40
Analysis
List Length
TitleCtrPubDate
Appl.NoApplicantInventorInt.Class
METHOD TO CONTROL APPETITE AND TREAT OBESITY
WO08.12.1994
PCT/US1994/005177MERCK & CO., INC.TOBERT, Jonathan, A.
A61K 38/17
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
The present invention relates to the administration of human apolipoprotein A-IV, isoforms and active fragments thereof, to humans as an injectable formulation for the purpose of controlling appetite and reducing food intake and body weight. The invention is also directed to an injectable pharmaceutical formulation of human apolipoprotein A-IV, or active fragments thereof.

METHOD OF TREATING NEURODEGENERATIVE DISEASES
WO09.03.2000
PCT/US1999/019654MERCK & CO., INC.BLOCK, Gilbert, A.
A61K 31/34
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
34
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
The present invention provides a method of treating a neurodegenerative disease, and in particular Alzheimer's disease, Mild Cognitive Impairment or other objective memory impairment which comprises the co-administration of ARICEPT or other cholinesterase inhibitor or cholenergic angonist and an effective amount of a selective COX-2 inhibitor. Although a wide range of COX-2 inhibitors may be employed in combination with ARICEPT, there are preferred choices which are specifically set forth herein.

ANDROGENIC AND BISPHOSPHONIC AGENTS COADMINISTERED TO TREAT DISEASES
WO04.06.1998
PCT/US1997/021306MERCK & CO., INC.SCHMIDT, Azriel
A61K 31/66
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
66
Phosphorus compounds
The inhibition of natural bone formation experienced in the prophylaxis and/or treatment of bone resorption disease with a bisphosphonic acid or a pharmaceutically acceptable salt thereof is overcome by the concommitant administration of an androgenic agent.

METHOD FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS
WO14.06.2001
PCT/US2000/033098MERCK & CO., INC.SPARROW, Carl, P.
A61K 38/17
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
The instant invention provides a method for raising serum HDL cholesterol levels comprising administering a therapeutically effective amount of an LXR ligand to a patient in need of such treatment. It further provides a method for using an LXR ligand to stimulate expression of the ABC1 gene. LXR ligands can be used for preventing and treating atherosclerosis and related conditions.

TREATMENT OF LOWER URINARY TRACT SYMPTOMS AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN
WO29.03.2001
PCT/US2000/025534MERCK & CO., INC.STONER, Elizabeth
A61K 31/505
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A medical condition in men known as Lower Urinary Tract Symptoms or LUTS is treated by the administration of a muscarinic receptor antagonist in combination with at least one of a 5α-reductase inhibitor and an α-adrenergic receptor blocker.

METHOD OF TREATING COLONIC ADENOMAS
WO06.02.1997
PCT/US1996/011761MERCK & CO., INC.KARGMAN, Stacia
A61K 31/00
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.

METHOD OF TREATING MIGRAINES AND PHARMACEUTICAL COMPOSITIONS
WO11.05.2000
PCT/US1999/025388MERCK & CO., INC.SIMITCHIEVA, Kremena
A61K 31/42
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42
Oxazoles
A combination of a 5HT1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.

INHIBITORS OF PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C
WO20.04.1995
PCT/US1994/011497MERCK & CO., INC.GIBBS, Jackson, B.
C07F 9/38
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
F
ACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
9
Compounds containing elements of the 5th Group of the Periodic System
02
Phosphorus compounds
28
with one or more P-C bonds
38
Phosphonic acids (R-P(:O)(OH)2); Thiophosphonic acids
The present invention is directed to novel α-hydroxy-phosphonate compounds which inhibit mammalian phosphoinositide-specific phospholipase-C. The compounds are potent inflammatory and analgesic agents and may be useful for the treatment of cancer.

METHODS AND COMPOSITIONS FOR TREATING ERECTILE DYSFUNCTION
WO14.09.2000
PCT/US2000/005711MERCK & CO., INC.STONER, Elizabeth
A61K 31/00
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
The present invention provides for a method for the treatment of erectile dysfunction in a male or female human subject in need of such treatment comprising administration of a therapeutically effective amount of an agonist of the melanocortin receptor in combination with a therapeutically effective amount of a cyclic-GMP-specific phosphodiesterase inhibitor or an alpha-adrenergic receptor antagonist. Further, the present invention provides for pharmaceutical compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating erectile dysfunction.

HUMAN C5a ANTAGONISTS AND AGONISTS
WO28.09.1995
PCT/US1995/003209MERCK & CO., INC.KONTEATIS, Zenon
A61K 38/00
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
The invention is an assay, including a series of peptides, which allow screening for inhibitors of C5a binding targeted to the subsite on the C5a a receptor occupied by the C-terminus of C5a. These peptides allow compound testing efforts to be targeted to this same subsite so that C5a agonists and antagonists can be identified. These peptides have much greater affinity (Ki∫10 nM) than does the natural C-terminus of C5a (Ki=300 νM) and have been labeled to allow for detection of molecules which inhibit binding of these peptides at this receptor subsite. The invention is useful to develop agonists, partial agonists, and antagonists of C5a, and the invention includes compounds identified according to the method of this invention and methods of their use.

Results 1-10 of 394 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 40